CTTN and esophageal squamous cell carcinoma: Patients with CTTN overexpression had significantly shorter disease-specific survival rate than those without CTTN overexpression in both I+IIA subgroup (n = 113, p = 0.001, Figure 3A) and IIB+III subgroup (n = 85, p = 0.027, Figure 3B), indicating that CTTN could be a valuable prognostic marker for ESCC.